Two clinical trials for the testing of an Alzheimer’s drug, have been canceled due to the lack of prospect of success.

analysis of an independent panel of experts had shown that the tested antibodies Aducanumab does not brake as expected the reduction of intellectual performance, had notified the company Biogen on Thursday.

Biogen had tested the substance for 2017, together with the Japanese pharmaceutical company Eisai for the market introduction. Safety concerns have played for the termination of the studies, no matter, – said Biogen. Hans-Ulrich Demuth Fraunhofer Institute for cell therapy and immunology, commented on the study From this: “Quite simply, It is a Disaster for the whole field.”